STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The third quarter of 2025 was an active and eventful quarter for AlzeCure Pharma. In July, we received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for our pain drug Painless ACD440 for the rare disease erythromelalgia. Furthermore, we carried out a rights issue of SEK 48.5 million, with an overallotment option of SEK 10 million. The rights issue was backed by all major shareholders, as well as by the company's Board of Directors and management group through subscription commitments. The rights issue was oversubscribed to 212% and generated total proceeds of SEK 58.5 million. We are very pleased and proud of this strong outcome and wish to thank all participants in the rights issue for their confidence in the plans on which the issue was based. We also presented and published new data for our pain projects ACD440 and TrkA-NAM. During the quarter, we further strengthened our organization by appointing Dr. Cecilia Wadell as Head of Development. She brings extensive experience in AlzeCure's therapeutic areas and will be responsible for leading our development efforts."
Martin Jönsson, CEO
Financial information for July - September 2025, Group
Figures in parentheses refer to the corresponding period of the previous year.
Net sales during the period totaled SEK 0 thousand (0).
Earnings for the period totaled SEK -10,025 thousand (-7,474).
Earnings per share, basic, totaled SEK -0.09 (-0.09).
Cash flow from operating activities totaled SEK -7,619 thousand (SEK -8,067).
Total assets at the end of the period amounted to SEK 66,591 thousand (47,554).
Cash and cash equivalents at the end of the period totaled SEK 59,190 thousand (39,187).
Financial information for January - September 2025, Group
Figures in parentheses refer to the corresponding period of the previous year.
Net sales during the period totaled SEK 0 thousand (0).
Earnings for the period totaled SEK -29,912 thousand (-25,994).
Earnings per share, basic, totaled SEK -0.31 (-0.35).
Cash flow from operating activities totaled SEK -26,012 thousand (SEK -26,819).
Total assets at the end of the period amounted to SEK 66,591 thousand (47,554).
Cash and cash equivalents at the end of the period totaled SEK 59,190 thousand (39,187).
AlzeCure Pharma AB (publ) acquired a newly formed subsidiary at the end of September 2025, which is currently dormant, to prepare the Group structure for any potential future needs. No operations have been conducted in the subsidiary; all business activities are carried out by the parent company, AlzeCure Pharma AB (publ). AlzeCure is therefore presenting consolidated financial statements for the first time.
Significant events during the period July - September 2025
On July 2, an extraordinary general meeting approved the decision on the new share issue.
On July 4, an information document regarding the Rights Issue was published, amended on July 7.
On July 15, the pain project ACD440 was granted Orphan Drug Designation in the US by the FDA.
On July 24, the outcome of the Rights Issue was presented. The issue was oversubscribed to 212%, and the company resolved on a directed share issue according to the previous resolution, including the overallotment option of SEK 10 million. Proceeds amounted to SEK 58.5 million before issue expenses, which were approximately SEK 4.0 million.
At the end of July, the company published a new scientific article presenting the results from the Phase IIa clinical trial with ACD440 in patients with chronic peripheral neuropathic pain.
In August, Cecilia Wadell was appointed as the new Head of Development.
In September, results for TrkA-NAM ACD137 and ACD440 were presented at the NeuPSIG pain conference in Berlin.
Significant events during the period January - June 2025
The company announced on February 17 that it has been awarded an EU grant for a Phase II clinical trial of NeuroRestore ACD856 for Alzheimer's disease.
In February, the company published a new scientific article demonstrating the unique mechanism of action behind Alzstatin, which is being developed for Alzheimer's disease.
In early April, the company presented new preclinical data for the lead drug candidate NeuroRestore ACD856 at the international Alzheimer's and Parkinson's Disease (AD/PD) conference in Vienna.
A new scientific article in Nature implicates NeuroRestore ACD856 as a potential treatment for obesity.
On April 9, the company announced that its Annual General Meeting would convene on May 14, 2025.
The company received a positive guidance response from the FDA in May regarding phase II/III studies with ACD440 in a rare disease.
In June, the company announced that its Board of Directors has resolved on a new share issue of approximately SEK 48.5 million with preferential rights for existing shareholders. In order to enable an additional capital raise, the Board may also resolve to exercise an over-allotment option of up to approximately SEK 10 million (the "Over-Allotment Option"). This proposal was subsequently approved at an extraordinary general meeting on July 2.
Significant events after the end of the period
No significant events have occurred after the end of the period.
The full report is attached as PDF and is available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. NeuroRestore has received an EU grant from the European Innovation Council and is being prepared for phase 2. Alzstatin focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless contains two projects: ACD440, which is a drug candidate for the treatment of neuropathic pain with positive phase 2 results and orphan drug designation from the FDA for the rare disease erythromelalgia, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Attachments
Alzecure Q3 2025 ENG
SOURCE: AlzeCure Pharma
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/alzecure-publishes-its-interim-report-for-january-september-2025-1100057